Physician profile
Deborah Smith
NPI 1912316613
$3,256.67
in general payments reported to CMS, 2019-2025
24 companies · $461 in 2025
The $461 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $39.92 · 2022: $498 · 2023: $451 · 2024: $1,807 · 2025: $461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,594 · Honoraria: $1,050 · Education: $74.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,593.76 |
| Honoraria | $1,050.00 |
| Education | $74.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Catalyst Pharmaceuticals, INC. | $1,158.09 | 2024 | |
| Pfizer INC. | $369.19 | 2022-2025 | |
| Celgene Corporation | $242.00 | 2022-2025 | Reblozyl |
| Janssen Biotech, INC. | $198.79 | 2022-2024 | Darzalex, Imbruvica |
| E.R. Squibb & Sons, L.L.C. | $194.45 | 2021-2025 | Reblozyl, Opdivo |
| Incyte Corporation | $183.05 | 2022-2024 | Monjuvi, Opzelura, Jakafi |
| Sobi, INC | $159.12 | 2023-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $142.91 | 2022 | |
| Glaxosmithkline, LLC. | $138.44 | 2024-2025 | Ojjaara, Jemperli, Zejula |
| Takeda Pharmaceuticals U.S.A., INC. | $80.56 | 2022-2025 | Ninlaro, Alunbrig |
| Genentech USA, INC. | $60.23 | 2025 | Itovebi, Polivy |
| Spectrum Pharmaceuticals INC. | $51.08 | 2024-2025 | Rolvedon |
| Tersera Therapeutics LLC | $44.11 | 2024-2025 | Zoladex |
| Jazz Pharmaceuticals INC. | $42.30 | 2021-2023 | |
| Mirati Therapeutics, INC. | $27.54 | 2023 | Krazati |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bioventus LLC | $21.68 | 2024 | Exogen Ultrasound Bone Healing System |
| Aveo Pharmaceuticals, INC. | $21.15 | 2025 | |
| Genmab U.S., INC. | $18.78 | 2024 | Epkinly |
| Gilead Sciences, INC. | $18.62 | 2025 | Trodelvy |
| Geron Corporation | $18.45 | 2025 | Rytelo |
| Fresenius Kabi USA, LLC | $17.50 | 2024 | Stimufend |
| Exelixis INC. | $17.20 | 2023 | Cabometyx |
| Abbvie INC. | $16.57 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.86 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.